{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:25:42Z","timestamp":1791062742837,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neurofilament light chain (NfL) is a structural axonal protein measurable in CSF and blood, increasingly investigated as a biomarker of neuroaxonal injury in clinical and research contexts. This review aims to explore the use of blood-based NfL as an endpoint in clinical trials of neurodegenerative conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A database search of MEDLINE and EMBASE was conducted to identify interventional clinical trials and\/or related post hoc analyses for neurodegenerative diseases, published between 2013 and 2024 that reported the use of serum or plasma NfL as an endpoint. Additional studies from reference lists of included trials were manually considered for inclusion where relevant. Data were charted descriptively by disease type and summarised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>49 studies were included, 29 in multiple sclerosis (MS), eight in amyotrophic lateral sclerosis (ALS), six in Alzheimer\u2019s disease (AD), and six in other diseases. Across studies, reductions in NfL often paralleled improvements in primary efficacy outcomes, supporting its use as a biomarker of disease activity and treatment response. However, several studies demonstrated a lack of concordance between change in NfL and in clinical outcomes, some of which may be related to the non-disease-modifying mechanisms of the interventions studied. This necessitates careful consideration when applying blood-based NfL as a biomarker endpoint for studies involving such interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Blood NfL is a promising biomarker with potential utility as a surrogate endpoint in neurological clinical trials, particularly for diseases with active axonal injury. Further validation, particularly around disease- and intervention-specific interpretation, is needed before blood NfL can be incorporated more routinely as a clinical endpoint.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-14007-5","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:52:13Z","timestamp":1784544733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review"],"prefix":"10.1007","volume":"273","author":[{"given":"Yuming","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oneil G.","family":"Bhalala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Sin","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-0060","authenticated-orcid":false,"given":"Nawaf","family":"Yassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"14007_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","volume":"233","author":"A Petzold","year":"2005","unstructured":"Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233:183\u2013198. https:\/\/doi.org\/10.1016\/j.jns.2005.03.015","journal-title":"J Neurol Sci"},{"key":"14007_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018309","volume":"9","author":"A Yuan","year":"2017","unstructured":"Yuan A, Rao MV, Veeranna NRA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 9:a018309. https:\/\/doi.org\/10.1101\/cshperspect.a018309","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"14007_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075091","volume":"8","author":"J Gaiottino","year":"2013","unstructured":"Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick JP, Monsch AU, Regeniter A, Lindberg RL, Kappos L, Leppert D, Petzold A, Giovannoni G, Kuhle J (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8:e75091. https:\/\/doi.org\/10.1371\/journal.pone.0075091","journal-title":"PLoS ONE"},{"key":"14007_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/d41573-023-00083-z","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A (2023) NfL makes regulatory debut as neurodegenerative disease biomarker. Nat Rev Drug Discov 22:431\u2013434. https:\/\/doi.org\/10.1038\/d41573-023-00083-z","journal-title":"Nat Rev Drug Discov"},{"key":"14007_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab086","volume":"3","author":"A Lle\u00f3","year":"2021","unstructured":"Lle\u00f3 A (2021) Biomarkers in neurological disorders: a fast-growing market. Brain Commun 3:fcab086. https:\/\/doi.org\/10.1093\/braincomms\/fcab086","journal-title":"Brain Commun"},{"key":"14007_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052231","volume":"26","author":"A Myrou","year":"2025","unstructured":"Myrou A, Barmpagiannos K, Ioakimidou A, Savopoulos C (2025) Molecular biomarkers in neurological diseases: advances in diagnosis and prognosis. Int J Mol Sci 26:2231. https:\/\/doi.org\/10.3390\/ijms26052231","journal-title":"Int J Mol Sci"},{"key":"14007_CR7","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-1195","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5, Liman V, Norgren N, Blennow K, Zetterberg H (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med CCLM. https:\/\/doi.org\/10.1515\/cclm-2015-1195","journal-title":"Clin Chem Lab Med CCLM"},{"key":"14007_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gissl\u00e9n","year":"2016","unstructured":"Gissl\u00e9n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H (2016) Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3:135\u2013140. https:\/\/doi.org\/10.1016\/j.ebiom.2015.11.036","journal-title":"EBioMedicine"},{"key":"14007_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D, Laforce RJ, Masellis M, Vandenberghe R, Ber IL, Otto M, van Minkelen R, Papma JM, Rombouts SA, Balasa M, \u00d6ijerstedt L, Jelic V, Dick KM, Cash DM, Harding SR, Jorge Cardoso M, Ourselin S, Rossor MN, Padovani A, Scarpini E, Fenoglio C, Tartaglia MC, Lamari F, Barro C, Kuhle J, Rohrer JD, Teunissen CE, van Swieten JC (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3:623\u2013636. https:\/\/doi.org\/10.1002\/acn3.325","journal-title":"Ann Clin Transl Neurol"},{"key":"14007_CR10","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1177\/1352458515623365","volume":"22","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, Yaldizli \u00d6, Regeniter A, Derfuss T, Canales M, Schluep M, Du Pasquier R, Krueger G, Granziera C (2016) Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler J 22:1550\u20131559. https:\/\/doi.org\/10.1177\/1352458515623365","journal-title":"Mult Scler J"},{"key":"14007_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81:857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954","journal-title":"Ann Neurol"},{"key":"14007_CR12","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1177\/1352458517715132","volume":"24","author":"F Piehl","year":"2017","unstructured":"Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, Olsson T (2017) Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler J 24:1046\u20131054. https:\/\/doi.org\/10.1177\/1352458517715132","journal-title":"Mult Scler J"},{"key":"14007_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"key":"14007_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S, Otto M, Piehl F, Ziemssen T, Bittner S, Sormani MP, Gattringer T, Abu-Rumeileh S, Thebault S, Abdelhak A, Green A, Benkert P, Kappos L, Comabella M, Tumani H, Freedman MS, Petzold A, Blennow K, Zetterberg H, Leppert D, Kuhle J (2024) Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application. Nat Rev Neurol 20:269\u2013287. https:\/\/doi.org\/10.1038\/s41582-024-00955-x","journal-title":"Nat Rev Neurol"},{"key":"14007_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1571605","author":"D Centonze","year":"2025","unstructured":"Centonze D, Di Sapio A, Brescia Morra V, Colombo E, Inglese M, Paolicelli D, Salvetti M, Furlan R (2025) Steps toward the implementation of neurofilaments in multiple sclerosis: patient profiles to be prioritized in clinical practice. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2025.1571605","journal-title":"Front Neurol"},{"key":"14007_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199739","volume":"26","author":"A Daponte","year":"2025","unstructured":"Daponte A, Koros C, Skarlis C, Siozios D, Rentzos M, Papageorgiou SG, Anagnostouli M (2025) Neurofilament biomarkers in neurology: from neuroinflammation to neurodegeneration, bridging established and novel analytical advances with clinical practice. Int J Mol Sci 26:9739. https:\/\/doi.org\/10.3390\/ijms26199739","journal-title":"Int J Mol Sci"},{"key":"14007_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\u00e7alp \u00d6, Straus SE (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"14007_CR18","unstructured":"Covidence systematic review software"},{"key":"14007_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"14007_CR20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/jnnp-2022-329221","volume":"93","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Cordano C, Boscardin WJ, Caverzasi E, Kuhle J, Chan B, Gelfand JM, Yiu HH, Oertel FC, Beaudry-Richard A, Montes SC, Oksenberg JR, Lago AL, Boxer A, Rojas-Martinez JC, Elahi FM, Chan JR, Green AJ (2022) Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. J Neurol Neurosurg Psychiatry 93:972\u2013977. https:\/\/doi.org\/10.1136\/jnnp-2022-329221","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14007_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-022-00427-8","volume":"12","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, Ludwig I, Willi R, Zalesak M, Ramanathan K, Kieseier BC, H\u00e4ring DA, Bagger M, Fox E (2022) Serum neurofilament light trajectories and their relation to subclinical radiological disease activity in relapsing multiple sclerosis patients in the APLIOS trial. Neurol Ther 12:303\u2013317. https:\/\/doi.org\/10.1007\/s40120-022-00427-8","journal-title":"Neurol Ther"},{"key":"14007_CR22","doi-asserted-by":"publisher","first-page":"104662","DOI":"10.1016\/j.ebiom.2023.104662","volume":"93","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or A, Thanei G-A, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE (2023) Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. PUBLISSO Ger Natl Libr Med 93:104662\u2013104662. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104662","journal-title":"PUBLISSO Ger Natl Libr Med"},{"key":"14007_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001102","volume":"9","author":"M Bock","year":"2021","unstructured":"Bock M, Steffen F, Zipp F, Bittner S (2021) Impact of dietary intervention on serum neurofilament light chain in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 9:e1102. https:\/\/doi.org\/10.1212\/nxi.0000000000001102","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"14007_CR24","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/acn3.51471","volume":"8","author":"PA Calabresi","year":"2021","unstructured":"Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, De Moor C, Sotirchos ES, Fisher E, Rudick RA, Sandrock A (2021) Measuring treatment response to advance precision medicine for multiple sclerosis. Ann Clin Transl Neurol 8:2166\u20132173. https:\/\/doi.org\/10.1002\/acn3.51471","journal-title":"Ann Clin Transl Neurol"},{"key":"14007_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/ene.15588","volume":"30","author":"C Camara\u2010Lemarroy","year":"2022","unstructured":"Camara\u2010Lemarroy C, Silva C, Gohill J, Yong VW, Koch M (2022) Serum neurofilament\u2010light and glial fibrillary acidic protein levels in hydroxychloroquine\u2010treated primary progressive multiple sclerosis. Eur J Neurol 30:187\u2013194. https:\/\/doi.org\/10.1111\/ene.15588","journal-title":"Eur J Neurol"},{"key":"14007_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/20552173231169463","author":"G Cutter","year":"2023","unstructured":"Cutter G, Rudick RA, de Moor C, Singh CM, Fisher E, Koster T, Lublin FD, Wolinsky JS, McFarland H, Jacobson S, Naylor ML (2023) Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: a post hoc analysis of the randomized CombiRx trial. Mult Scler J Exp Transl Clin. https:\/\/doi.org\/10.1177\/20552173231169463","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"14007_CR27","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/wnl.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92:e1007\u2013e1015. https:\/\/doi.org\/10.1212\/wnl.0000000000007032","journal-title":"Neurology"},{"key":"14007_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/acn3.795","volume":"6","author":"MP Sormani","year":"2019","unstructured":"Sormani MP, Haering D, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J (2019) Blood neurofilament light as a potential endpoint in phase 2 studies in MS. Ann Clin Transl Neurol 6:1081\u20131089. https:\/\/doi.org\/10.1002\/acn3.795","journal-title":"Ann Clin Transl Neurol"},{"key":"14007_CR29","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1111\/ene.15009","volume":"28","author":"S Harris","year":"2021","unstructured":"Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA (2021) Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of Phase 3 ozanimod trials. Eur J Neurol 28:3722\u20133730. https:\/\/doi.org\/10.1111\/ene.15009","journal-title":"Eur J Neurol"},{"key":"14007_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/nejmoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, H\u00e4ring DA, Ramanathan K, Merschhemke M, Kappos L (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383:546\u2013557. https:\/\/doi.org\/10.1056\/nejmoa1917246","journal-title":"N Engl J Med"},{"key":"14007_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/13524585211032348","volume":"28","author":"J Kuhle","year":"2021","unstructured":"Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, R\u04e7sch N, Kaiser C, Mitchell CP, Leppert D, Havari E, Kappos L (2021) Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing\u2013remitting MS. Mult Scler J 28:573\u2013582. https:\/\/doi.org\/10.1177\/13524585211032348","journal-title":"Mult Scler J"},{"key":"14007_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-321321","volume":"90","author":"T Sejbaek","year":"2019","unstructured":"Sejbaek T, Nielsen HH, Penner N, Plavina T, Mendoza JP, Martin NA, Elkjaer ML, Ravnborg MH, Illes Z (2019) Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients. J Neurol Neurosurg Psychiatry 90:jnnp-321321. https:\/\/doi.org\/10.1136\/jnnp-2019-321321","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14007_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65215-6","author":"KH St\u00fcrner","year":"2020","unstructured":"St\u00fcrner KH, Werz O, Koeberle A, Otto M, Pless O, Leypoldt F, Paul F, Heesen C (2020) Lipid mediator profiles predict response to therapy with an oral frankincense extract in relapsing-remitting multiple sclerosis. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-020-65215-6","journal-title":"Sci Rep"},{"key":"14007_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000598","volume":"6","author":"S Thebault","year":"2019","unstructured":"Thebault S, R Tessier D, Lee H, Bowman M, Bar-Or A, Arnold DL, L Atkins H, Tabard-Cossa V, Freedman MS (2019) High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurol Neuroimmunol Neuroinflamm 6:e598. https:\/\/doi.org\/10.1212\/NXI.0000000000000598","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"14007_CR35","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/acn3.51045","volume":"7","author":"S Thebault","year":"2020","unstructured":"Thebault S, Lee H, Bose G, Tessier D, Abdoli M, Bowman MA, Berard JA, Walker LAS, Rush C, MacLean H, Booth RA, Narayanan S, Arnold DL, Tabard-Cossa V, Atkins HL, Bar-Or A, Freedman MS (2020) Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Ann Clin Transl Neurol 7:767\u2013775. https:\/\/doi.org\/10.1002\/acn3.51045","journal-title":"Ann Clin Transl Neurol"},{"key":"14007_CR36","doi-asserted-by":"publisher","first-page":"104670","DOI":"10.1016\/j.msard.2023.104670","volume":"73","author":"U Oh","year":"2023","unstructured":"Oh U, Woolbright E, Lehner-Gulotta D, Coleman R, Conaway M, Goldman MD, Brenton JN (2023) Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet. Mult Scler Relat Disord 73:104670\u2013104670. https:\/\/doi.org\/10.1016\/j.msard.2023.104670","journal-title":"Mult Scler Relat Disord"},{"key":"14007_CR37","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1177\/1352458520986956","volume":"27","author":"RJ Fox","year":"2021","unstructured":"Fox RJ, Raska P, Barro C, Karafa M, Konig V, Bermel RA, Chase M, Coffey CS, Goodman AD, Klawiter EC, Naismith RT, Kuhle J (2021) Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Mult Scler J 27:2014\u20132022. https:\/\/doi.org\/10.1177\/1352458520986956","journal-title":"Mult Scler J"},{"key":"14007_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001130","volume":"9","author":"TE Williams","year":"2022","unstructured":"Williams TE, Holdsworth KP, Nicholas JM, Eshaghi A, Katsanouli T, Wellington H, Heslegrave A, Zetterberg H, Frost C, Chataway J (2022) Assessing neurofilaments as biomarkers of neuroprotection in progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 9:e1130. https:\/\/doi.org\/10.1212\/nxi.0000000000001130","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"14007_CR39","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1007\/s00415-022-10989-0","volume":"269","author":"C Alcal\u00e1","year":"2022","unstructured":"Alcal\u00e1 C, Quintanilla-Bord\u00e1s C, Gasc\u00f3n F, Sempere \u00c1P, Navarro L, Carcel\u00e9n-Gadea M, Landete L, Mallada J, Ca\u00f1izares E, Belenguer A, Carratal\u00e1 S, Dom\u00ednguez JA, P\u00e9rez-Miralles FC, Gil-Perot\u00edn S, Gasqu\u00e9 R, Cubas L, Castillo J, Casanova B (2022) Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study. J Neurol 269:3676\u20133681. https:\/\/doi.org\/10.1007\/s00415-022-10989-0","journal-title":"J Neurol"},{"key":"14007_CR40","doi-asserted-by":"publisher","first-page":"205521731988719","DOI":"10.1177\/2055217319887198","volume":"5","author":"LE Baldassari","year":"2019","unstructured":"Baldassari LE, Planchon SM, Bermel RA, Nakamura K, Fisher E, Feng J, Sakaie KE, Ontaneda D, Cohen JA (2019) Serum neurofilament light chain concentration in a phase 1\/2 trial of autologous mesenchymal stem cell transplantation. Mult Scler J Exp Transl Clin 5:205521731988719\u2013205521731988719. https:\/\/doi.org\/10.1177\/2055217319887198","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"14007_CR41","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1177\/13524585231176732","volume":"29","author":"X Jiang","year":"2023","unstructured":"Jiang X, Shen C, Teunissen CE, Wessels M, Zetterberg H, Giovannoni G, Singh CM, Caba B, Elliott C, Fisher E, de Moor C, Belachew S, Gafson AR (2023) Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation. Mult Scler J 29:1070\u20131079. https:\/\/doi.org\/10.1177\/13524585231176732","journal-title":"Mult Scler J"},{"key":"14007_CR42","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000982","volume":"8","author":"N Joisten","year":"2021","unstructured":"Joisten N, Rademacher A, Warnke C, Proschinger S, Schenk A, Walzik D, Knoop A, Thevis M, Steffen F, Bittner S, Gonzenbach R, Kool J, Bloch W, Bansi J, Zimmer P (2021) Exercise diminishes plasma neurofilament light chain and reroutes the kynurenine pathway in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 8:e982. https:\/\/doi.org\/10.1212\/nxi.0000000000000982","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"14007_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.718895","author":"T Moser","year":"2021","unstructured":"Moser T, Seiberl M, Feige J, Bieler L, Radlberger RF, O\u2019Sullivan C, Pilz G, Harrer A, Schwenker K, Haschke-Becher E, Machegger L, Grimm J, Redlberger-Fritz M, Buchmann A, Khalil M, Kvas E, Trinka E, Wipfler P (2021) Tetravalent influenza vaccine is not associated with neuroaxonal damage in multiple sclerosis patients. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.718895","journal-title":"Front Immunol"},{"key":"14007_CR44","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/wnl.0000000000003653","volume":"88","author":"J Kuhle","year":"2017","unstructured":"Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli \u00d6, Pelletier D, Giovannoni G, Waubant E, Gnanapavan S (2017) Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88:826\u2013831. https:\/\/doi.org\/10.1212\/wnl.0000000000003653","journal-title":"Neurology"},{"key":"14007_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1772","author":"K H\u00e4nninen","year":"2020","unstructured":"H\u00e4nninen K, J\u00e4\u00e4skel\u00e4inen O, Herukka S, Soilu\u2010H\u00e4nninen M (2020) Vitamin D supplementation and serum neurofilament light chain in interferon\u2010beta\u20101b\u2010treated MS patients. Brain Behav. https:\/\/doi.org\/10.1002\/brb3.1772","journal-title":"Brain Behav"},{"key":"14007_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/ane.13037","volume":"139","author":"T Holm\u00f8y","year":"2018","unstructured":"Holm\u00f8y T, R\u00f8sj\u00f8 E, Zetterberg H, Blennow K, Lindstr\u00f8m JC, Steffensen LH, Kampman MT (2018) Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta Neurol Scand 139:172\u2013176. https:\/\/doi.org\/10.1111\/ane.13037","journal-title":"Acta Neurol Scand"},{"key":"14007_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/ane.13185","volume":"141","author":"J Smolders","year":"2019","unstructured":"Smolders J, Mimpen M, Oechtering J, Damoiseaux J, Ouweland J, Hupperts R, Kuhle J (2019) Vitamin D 3 supplementation and neurofilament light chain in multiple sclerosis. Acta Neurol Scand 141:77\u201380. https:\/\/doi.org\/10.1111\/ane.13185","journal-title":"Acta Neurol Scand"},{"key":"14007_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000856","author":"DA H\u00e4ring","year":"2020","unstructured":"H\u00e4ring DA, Kropshofer H, Kappos L, Cohen JA, Shah A, Meinert R, Leppert D, Tomic D, Kuhle J (2020) Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000000856","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"14007_CR49","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.celrep.2016.05.009","volume":"15","author":"IY Choi","year":"2016","unstructured":"Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, Suarez J, Michalsen A, Cross AH, Morgan TE, Wei M, Paul F, Bock M, Longo VD (2016) Diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep 15:2136\u20132146. https:\/\/doi.org\/10.1016\/j.celrep.2016.05.009","journal-title":"Cell Rep"},{"key":"14007_CR50","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jnnp-2022-329074","volume":"93","author":"JN Brenton","year":"2022","unstructured":"Brenton JN, Lehner-Gulotta D, Woolbright E, Banwell B, Bergqvist AGC, Chen S, Coleman R, Conaway M, Goldman MD (2022) Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits. J Neurol Neurosurg Psychiatry 93:637\u2013644. https:\/\/doi.org\/10.1136\/jnnp-2022-329074","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14007_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b14\u03b2l integrin. Nature 356:63\u201366. https:\/\/doi.org\/10.1038\/356063a0","journal-title":"Nature"},{"key":"14007_CR52","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/nejmoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910. https:\/\/doi.org\/10.1056\/nejmoa044397","journal-title":"N Engl J Med"},{"key":"14007_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/s1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung H-P, Havrdov\u00e1 EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D, Bartholom\u00e9 E, D\u2019Hooghe M, Pandolfo M, Van Wijmeersch B, Bhan V, Blevins G, Brunet D, Devonshire V, Duquette P, Freedman M, Grand\u2019Maison F, Jacques F, Lapierre Y, Lee L, Morrow S, Yeung M, Dufek M, Havrdov\u00e1 EK, Kanovsky P, Stetkarova I, Talabova M, Frederiksen J, Kant M, Petersen T, Ravnborg M, Sellebjerg F, Airas L, Elovaara I, Eralinna J-P, Sarasoja T, Al Khedr A, Brassat D, Brochet B, Camu W, Debouverie M, Laplaud D, Lebrun Frenay C, Pelletier J, Vermersch P, Vukusi S, Baum K, Berthele A, Faiss J, Flachenecker P, Hohlfeld R, Krumbholz M, Lassek C, Maeurer M, Meuth S, Ziemssen T, Hardiman O, McGuigan C, Achiron A, Karussis D, Bergamaschi R, Morra VB, Comi G, Cottone S, Grimaldi L, Mancardi GL, Massacesi L, Nocentini U, Salvetti M, Scarpini E, Sola P, Tedeschi G, Trojano M, Zaffaroni M, Frequin S, Hupperts R, Killestein J, Schrijver H, Van Dijl R, van Munster E, Czarnecki M, Drozdowski W, Fryze W, Hertmanowska H, Ilkowski J, Kaminska A, Klodowska-Duda G, Maciejowski M, Motta E, Podemski R, Potemkowski A, Rog T, Selmaj K, Stelmasiak Z, Stepien A, Tutaj A, Zaborski J, Boyko A, Chefranova Z, Evdoshenko E, Khabirov F, Sivertseva S, Yakupov E, Alvarez Cerme\u00f1o JC, Escartin A, Fernandez OF, Garcia-Merino A, Hernandez Perez MA, Ayuso GI, Lallana JM, Gairin XM, Oreja-Guevara C, Saiz Hinarejos A, Gunnarsson M, Lycke J, Martin C, Piehl F, Roshanisefat H, Sundstrom P, Duddy M, Gran B, Harrower T, Hobart J, Kapoor R, Lee M, Mattison P, Nicholas R, Pearson O, Rashid W, Rog D, Sharrack B, Silber E, Turner B, Williams A, Woolmore J, Young C, Bandari D, Berger J, Camac A, Cohan S, Conway J, Edwards K, Fabian M, Florin J, Freedman S, Garwacki D, Goldman M, Harrison D, Herrman C, Huang D, Javed A, Jeffery D, Kamin S, Katsamakis G, Khatri B, Langer-Gould A, Lynch S, Mattson D, Miller T, Miravalle A, Moses H, Muley S, Napier J, Nielsen A, Pachner A, Pardo G, Picone M, Robertson D, Royal W, Sheppard C, Thrower B, Twyman C, Waubant E, Wendt J, Yadav V, Zabad R, Zarelli G (2018) Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 17:405\u2013415. https:\/\/doi.org\/10.1016\/s1474-4422(18)30069-3","journal-title":"Lancet Neurol"},{"key":"14007_CR54","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211044479","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, H\u00e4ring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ (2021) Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler J. https:\/\/doi.org\/10.1177\/13524585211044479","journal-title":"Mult Scler J"},{"key":"14007_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/nejmoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221\u2013234. https:\/\/doi.org\/10.1056\/nejmoa1601277","journal-title":"N Engl J Med"},{"key":"14007_CR56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/nejmoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209\u2013220. https:\/\/doi.org\/10.1056\/nejmoa1606468","journal-title":"N Engl J Med"},{"key":"14007_CR57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/nejmoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401. https:\/\/doi.org\/10.1056\/nejmoa0909494","journal-title":"N Engl J Med"},{"key":"14007_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415. https:\/\/doi.org\/10.1056\/NEJMoa0907839","journal-title":"N Engl J Med"},{"key":"14007_CR59","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/s1474-4422(19)30239-x","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung H-P, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 18:1009\u20131020. https:\/\/doi.org\/10.1016\/s1474-4422(19)30239-x","journal-title":"Lancet Neurol"},{"key":"14007_CR60","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/s1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung H-P, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 18:1021\u20131033. https:\/\/doi.org\/10.1016\/s1474-4422(19)30238-8","journal-title":"Lancet Neurol"},{"key":"14007_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2006.02.053","volume":"538","author":"LCD Gibson","year":"2006","unstructured":"Gibson LCD, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, MacKenzie FL, Nagasawa M, Stevens PA, MacKenzie SJ (2006) The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 538:39\u201342. https:\/\/doi.org\/10.1016\/j.ejphar.2006.02.053","journal-title":"Eur J Pharmacol"},{"key":"14007_CR62","doi-asserted-by":"publisher","first-page":"11313","DOI":"10.1073\/pnas.1002716107","volume":"107","author":"Y Cho","year":"2010","unstructured":"Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K, Lolis EJ (2010) Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U S A 107:11313\u201311318. https:\/\/doi.org\/10.1073\/pnas.1002716107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14007_CR63","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1212\/WNL.0000000000011314","volume":"96","author":"RT Naismith","year":"2021","unstructured":"Naismith RT, Bermel RA, Coffey CS, Goodman AD, Fedler J, Kearney M, Klawiter EC, Nakamura K, Narayanan S, Goebel C, Yankey J, Klingner E, Fox RJ (2021) Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study. Neurology 96:e491\u2013e500. https:\/\/doi.org\/10.1212\/WNL.0000000000011314","journal-title":"Neurology"},{"key":"14007_CR64","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/nejmoa1803583","volume":"379","author":"RJ Fox","year":"2018","unstructured":"Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A (2018) Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med 379:846\u2013855. https:\/\/doi.org\/10.1056\/nejmoa1803583","journal-title":"N Engl J Med"},{"key":"14007_CR65","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","volume":"74","author":"F Barkhof","year":"2010","unstructured":"Barkhof F, Hulst HE, Drulovic J, Uitdehaag BMJ, Matsuda K, Landin R, MN166-001 Investigators (2010) Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 74:1033\u20131040. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d7d651","journal-title":"Neurology"},{"key":"14007_CR66","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/s0140-6736(13)62242-4","volume":"383","author":"J Chataway","year":"2014","unstructured":"Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CRM, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383:2213\u20132221. https:\/\/doi.org\/10.1016\/s0140-6736(13)62242-4","journal-title":"Lancet"},{"key":"14007_CR67","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/00048674231187312","volume":"58","author":"D Eratne","year":"2023","unstructured":"Eratne D, Kang M, Malpas C, Simpson-Yap S, Lewis C, Dang C, Grewal J, Coe A, Dobson H, Keem M, Chiu W-H, Kalincik T, Ooi S, Darby D, Brodtmann A, Hansson O, Janelidze S, Blennow K, Zetterberg H, Walker A, Dean O, Berk M, Wannan C, Pantelis C, Loi SM, Walterfang M, Berkovic SF, Santillo AF, Velakoulis D, The MiND Study Group (2023) Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders. Aust N Z J Psychiatry 58:70\u201381. https:\/\/doi.org\/10.1177\/00048674231187312","journal-title":"Aust N Z J Psychiatry"},{"key":"14007_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P, Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 11:812. https:\/\/doi.org\/10.1038\/s41467-020-14612-6","journal-title":"Nat Commun"},{"key":"14007_CR69","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74:557. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117","journal-title":"JAMA Neurol"},{"key":"14007_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1132808","author":"F Verde","year":"2023","unstructured":"Verde F, Milone I, Colombo E, Maranzano A, Solca F, Torre S, Doretti A, Gentile F, Manini A, Bonetti R, Peverelli S, Messina S, Maderna L, Morelli C, Poletti B, Ratti A, Silani V, Ticozzi N (2023) Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2023.1132808","journal-title":"Front Aging Neurosci"},{"key":"14007_CR71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ene.15573","volume":"30","author":"E Beghi","year":"2022","unstructured":"Beghi E, Pupillo E, Bianchi E, Bonetto V, Luotti S, Pasetto L, Bendotti C, Tortarolo M, Sironi F, Camporeale L, Sherman AV, Paganoni S, Scognamiglio A, De Marchi F, Bongioanni P, Del Carratore R, Caponnetto C, Diamanti L, Martinelli D, Calvo A, Filosto M, Padovani A, Piccinelli SC, Ricci C, Giacoma SD, Angelis ND, Inghilleri M, Spataro R, Bella VL, Logroscino G, Lunetta C, Tarlarini C, Mandrioli J, Martinelli I, Simonini C, Zucchi E, Monsurr\u00f2 MR, Ricciardi D, Trojsi F, Riva N, Filippi M, Simone IL, Sorar\u00f9 G, Spera C, Florio L, Messina S, Russo M, Siciliano G, Conte A, Saddi MV, Carboni N, Mazzini L, Enia G, Zucchella A, Pinzani L, Giorgi LD, Nicoletti C, Semprucci E, Arippol ED, Giussani G, Graziani M, Ferrari C, Cantello R, Bersano E, Dolciotti C, Masciandaro SM, Da Prato I, Cabona C, Meo G, Ceroni M, Dal Fabbro B, Chi\u00f2 A, Moglia C, Manera U, Fuda G, Casale F, De Marco G, Salamone P, Giannini F, Bocci S, Ceccanti M, Cambieri C, Libonati L, Moret F, Frasca V, Coletti T, Tortelli R, Capozzo R, Gerardi F, Sansone V, Fini N, Gianferrari G, Gessani A, Falzone Y, Schito P, Pozzi L, Domi T, D\u2019Errico E, Morea A, Milella G (2022) Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Eur J Neurol 30:69\u201386. https:\/\/doi.org\/10.1111\/ene.15573","journal-title":"Eur J Neurol"},{"key":"14007_CR72","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1111\/ene.16020","volume":"30","author":"DN Weemering","year":"2023","unstructured":"Weemering DN, Midei M, Milner P, Gopalakrishnan V, Kumar A, Dannenberg AJ, Bunte TM, Foucher J, Ingre C, \u0136\u0113ni\u0146a V, Rallmann K, van den Berg LH, van Eijk RPA (2023) A randomized, double\u2010blind, placebo\u2010controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis. Eur J Neurol 30:3722\u20133731. https:\/\/doi.org\/10.1111\/ene.16020","journal-title":"Eur J Neurol"},{"key":"14007_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16154","volume":"31","author":"S Witzel","year":"2023","unstructured":"Witzel S, Statland JM, Steinacker P, Otto M, Dorst J, Schuster J, Barohn RJ, Ludolph AC (2023) Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis-insights from a completed randomized controlled trial with rasagiline. Eur J Neurol 31:e16154. https:\/\/doi.org\/10.1111\/ene.16154","journal-title":"Eur J Neurol"},{"key":"14007_CR74","doi-asserted-by":"publisher","first-page":"102672","DOI":"10.1016\/j.nicl.2021.102672","volume":"30","author":"S Babu","year":"2021","unstructured":"Babu S, Hightower BG, Chan J, Z\u00fcrcher NR, Kivis\u00e4kk P, Tseng C-EJ, Sanders DL, Robichaud A, Banno H, Evora A, Ashokkumar A, Pothier L, Paganoni S, Chew S, Dojillo J, Matsuda K, Gudesblatt M, Berry JD, Cudkowicz ME, Hooker JM, Atassi N (2021) Ibudilast (MN-166) in amyotrophic lateral sclerosis\u2014an open label, safety and pharmacodynamic trial. NeuroImage Clin 30:102672\u2013102672. https:\/\/doi.org\/10.1016\/j.nicl.2021.102672","journal-title":"NeuroImage Clin"},{"key":"14007_CR75","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000027421","volume":"100","author":"RD Henderson","year":"2021","unstructured":"Henderson RD, Agosti JM, McCombe PA, Thorpe K, Heggie S, Heshmat S, Appleby MW, Ziegelaar BW, Crowe DT, Redlich GL (2021) Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore) 100:e27421. https:\/\/doi.org\/10.1097\/md.0000000000027421","journal-title":"Medicine (Baltimore)"},{"key":"14007_CR76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/acn3.51491","volume":"9","author":"JS Katz","year":"2022","unstructured":"Katz JS, Rothstein JD, Cudkowicz ME, Genge A, Oskarsson H, Hains AB, Chen C, Galanter J, Burgess BL, Cho W, Kerchner GA, Yeh FL, Ghosh AS, Cheeti S, Brooks L, Honigberg L, Couch JA, Rothenberg ME, Brunstein F, Sharma KR, Berry JD, Glass JD (2022) A phase 1 study of GDC\u20100134, a dual leucine zipper kinase inhibitor, in ALS. Ann Clin Transl Neurol 9:50\u201366. https:\/\/doi.org\/10.1002\/acn3.51491","journal-title":"Ann Clin Transl Neurol"},{"key":"14007_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102844","author":"W Camu","year":"2020","unstructured":"Camu W, Mickunas M, Veyrune J-L, Payan C, Garlanda C, Locati M, Juntas-Morales R, Pageot N, Malaspina A, Andreasson U, Kirby J, Suehs C, Saker S, Masseguin C, Vos JD, Zetterberg H, Shaw PJ, Al-Chalabi A, Leigh PN, Tree T, Bensimon G (2020) Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102844","journal-title":"EBioMedicine"},{"key":"14007_CR78","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/nejmoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chi\u00f2 A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387:1099\u20131110. https:\/\/doi.org\/10.1056\/nejmoa2204705","journal-title":"N Engl J Med"},{"key":"14007_CR79","unstructured":"U.S. Food and Drug Administration (2023) FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. FDA"},{"key":"14007_CR80","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/ane.13078","volume":"139","author":"P de Flon","year":"2019","unstructured":"de Flon P, Laurell K, Sundstr\u00f6m P, Blennow K, S\u00f6derstr\u00f6m L, Zetterberg H, Gunnarsson M, Svenningsson A (2019) Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurol Scand 139:462\u2013468. https:\/\/doi.org\/10.1111\/ane.13078","journal-title":"Acta Neurol Scand"},{"key":"14007_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1108191","author":"KS Frederiksen","year":"2023","unstructured":"Frederiksen KS, Jensen CS, H\u00f8gh P, Gergelyffy R, Waldemar G, Andersen BB, Gottrup H, Vestergaard K, Wermuth L, S\u00f8ndergaard HB, Sellebjerg F, Hasselbalch SG, Simonsen AH (2023) Aerobic exercise does not affect serum neurofilament light in patients with mild Alzheimer\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2023.1108191","journal-title":"Front Neurosci"},{"key":"14007_CR82","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/adr-210302","volume":"5","author":"D Li","year":"2021","unstructured":"Li D, Zhang L, Nelson NW, Mielke MM, Yu F (2021) Plasma neurofilament light and future declines in cognition and function in Alzheimer\u2019s disease in the FIT-AD trial. J Alzheimers Dis Rep 5:601\u2013611. https:\/\/doi.org\/10.3233\/adr-210302","journal-title":"J Alzheimers Dis Rep"},{"key":"14007_CR83","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/JAD-150817","volume":"50","author":"K Hoffmann","year":"2016","unstructured":"Hoffmann K, Sobol NA, Frederiksen KS, Beyer N, Vogel A, Vestergaard K, Br\u00e6ndgaard H, Gottrup H, Lolk A, Wermuth L, Jacobsen S, Laugesen LP, Gergelyffy RG, H\u00f8gh P, Bjerregaard E, Andersen BB, Siersma V, Johannsen P, Cotman CW, Waldemar G, Hasselbalch SG (2016) Moderate-to-high intensity physical exercise in patients with Alzheimer\u2019s disease: a randomized controlled trial. J Alzheimers Dis 50:443\u2013453. https:\/\/doi.org\/10.3233\/JAD-150817","journal-title":"J Alzheimers Dis"},{"key":"14007_CR84","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3233\/jad-201100","volume":"80","author":"F Yu","year":"2021","unstructured":"Yu F, Vock DM, Zhang L, Salisbury D, Nelson NW, Chow LS, Smith G, Barclay TR, Dysken M, Wyman JF (2021) Cognitive effects of aerobic exercise in Alzheimer\u2019s disease: a pilot randomized controlled trial. J Alzheimers Dis 80:233\u2013244. https:\/\/doi.org\/10.3233\/jad-201100","journal-title":"J Alzheimers Dis"},{"key":"14007_CR85","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/adr-210296","volume":"5","author":"AC Lo","year":"2021","unstructured":"Lo AC, Evans CD, Mancini M, Wang H, Shcherbinin S, Lu M, Natanegara F, Willis BA (2021) Phase II (NAVIGATE-AD study) results of LY3202626 effects on patients with mild Alzheimer\u2019s disease dementia. J Alzheimers Dis Rep 5:321\u2013336. https:\/\/doi.org\/10.3233\/adr-210296","journal-title":"J Alzheimers Dis Rep"},{"key":"14007_CR86","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3392","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA (2022) Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392","journal-title":"JAMA Neurol"},{"key":"14007_CR87","doi-asserted-by":"publisher","first-page":"256","DOI":"10.14283\/jpad.2020.6","volume":"7","author":"H-Y Wang","year":"2020","unstructured":"Wang H-Y, Pei Z, Lee K-C, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH (2020) PTI-125 reduces biomarkers of Alzheimer\u2019s disease in patients. J Prev Alzheimers Dis 7:256\u2013264. https:\/\/doi.org\/10.14283\/jpad.2020.6","journal-title":"J Prev Alzheimers Dis"},{"key":"14007_CR88","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2100708","journal-title":"N Engl J Med"},{"key":"14007_CR89","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 76:791. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0765","journal-title":"JAMA Neurol"},{"key":"14007_CR90","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","volume":"94","author":"O Aktas","year":"2023","unstructured":"Aktas O, Hartung H-P, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BA (2023) Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry 94:757\u2013768. https:\/\/doi.org\/10.1136\/jnnp-2022-330412","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14007_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2023.2232520","volume":"31","author":"S Ticau","year":"2024","unstructured":"Ticau S, Aldinc E, Polydefkis M, Adams D, Coelho T, Ueda M, Hale C, Vest J, Nioi P, Patisiran Global OLE Collaborators (2024) Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid 31:1\u201311. https:\/\/doi.org\/10.1080\/13506129.2023.2232520","journal-title":"Amyloid"},{"key":"14007_CR92","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/mds.28923","volume":"37","author":"J Palma","year":"2022","unstructured":"Palma J, Martinez J, Millar Vernetti P, Ma T, Perez MA, Zhong J, Qian Y, Dutta S, Maina KN, Siddique I, Bitan G, Ades-Aron B, Shepherd TM, Kang UJ, Kaufmann H (2022) MTOR inhibition with sirolimus in multiple system atrophy: a randomized, double-blind, placebo-controlled futility trial and 1-year biomarker longitudinal analysis. Mov Disord 37:778\u2013789. https:\/\/doi.org\/10.1002\/mds.28923","journal-title":"Mov Disord"},{"key":"14007_CR93","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon H-K, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H, Ahmed A, Aiba I, Albanese A, Bertram K, Bordelon Y, Bower J, Brosch J, Claassen D, Colosimo C, Corvol J-C, Cudia P, Daniele A, Defebvre L, Driver-Dunckley E, Duquette A, Eleopra R, Eusebio A, Fung V, Geldmacher D, Golbe L, Grandas F, Hall D, Hatano T, H\u00f6glinger GU, Honig L, Hui J, Kerwin D, Kikuchi A, Kimber T, Kimura T, Kumar R, Litvan I, Ljubenkov P, Lorenzl S, Ludolph A, Mari Z, McFarland N, Meissner W, Mir Rivera P, Mochizuki H, Morgan J, Munhoz R, Nishikawa N, O\u2019Sullivan J, Oeda T, Oizumi H, Onodera O, Ory-Magne F, Peckham E, Postuma R, Quattrone A, Quinn J, Ruggieri S, Sarna J, Schulz PE, Slevin J, Tagliati M, Wile D, Wszolek Z, Xie T, Zesiewicz T (2021) Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 20:182\u2013192. https:\/\/doi.org\/10.1016\/s1474-4422(20)30489-0","journal-title":"Lancet Neurol"},{"key":"14007_CR94","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s13365-023-01116-4","volume":"29","author":"L Thela","year":"2023","unstructured":"Thela L, Decloedt E, Zetterberg H, Gissl\u00e9n M, Lesosky M, Gleich M, Koutsilieri E, Scheller C, Hye A, Joska J (2023) Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial. J Neurovirol 29:156\u2013166. https:\/\/doi.org\/10.1007\/s13365-023-01116-4","journal-title":"J Neurovirol"},{"key":"14007_CR95","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","volume":"270","author":"N Cebulla","year":"2023","unstructured":"Cebulla N, Schirmer D, Runau E, Flamm L, Gommersbach S, Stengel H, Zhou X, Einsele H, Reinhold A-K, Rogalla von Bieberstein B, Zeller D, Rittner H, Kort\u00fcm KM, Sommer C (2023) Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment. J Neurol 270:2997\u20133007. https:\/\/doi.org\/10.1007\/s00415-023-11624-2","journal-title":"J Neurol"},{"key":"14007_CR96","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09917-x","author":"T Williams","year":"2020","unstructured":"Williams T, Zetterberg H, Chataway J (2020) Neurofilaments in progressive multiple sclerosis: a systematic review. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-09917-x","journal-title":"J Neurol"},{"key":"14007_CR97","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","volume":"8","author":"RL Prentice","year":"1989","unstructured":"Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8:431\u2013440. https:\/\/doi.org\/10.1002\/sim.4780080407","journal-title":"Stat Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14007-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14007-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14007-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:49:06Z","timestamp":1786348146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14007-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["14007"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14007-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Oneil G Bhalala has received honoraria for educational activities from Eli Lilly. Nawaf Yassi has received honoraria for educational activities from Eli Lilly and Novo Nordisk. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"476"}}